

**1-Phthalimido-8-(tosyloxy)-3,6-dioxaoctane (9).** To a solution of **8** (5.0 g, 0.018 mol) in dry pyridine (20 mL) was added over a 1-h period *p*-toluenesulfonyl chloride (6.82 g, 0.036 mol) at 0–5 °C. After stirring for 3 h at 23 °C, the mixture was poured onto a mixture of HCl (25 mL) and ice, and the product was extracted with EtOAc (25 mL × 4). After removal of the solvent in vacuo, the crude product was chromatographed on silica gel with EtOAc–hexane (1:1) to give an oil (6 g, 77%), which solidified upon cooling: mp 80–81 °C;  $R_f$  0.33 (silica gel, EtOAc–hexane, 1:1); EIMS,  $m/e$  432 ( $M - 1$ ); NMR ( $CDCl_3$ )  $\delta$  7.84 and 7.71 (4 H, d and m, phthalimide, Ar), 7.77 and 7.44 (4 H, q, Ts, Ar), 4.18–3.48 (12 H, t and m,  $CH_2O$ ), 2.44 (3 H, s,  $CH_3$ ). Anal. ( $C_{21}H_{23}NO_7S$ ), C, H, N.

**1-Phthalimido-8-( $\beta$ -naltrexamino)-3,6-dioxaoctane Dihydrochloride (6·2HCl).** A mixture of **9** (650 mg, 1.5 mmol),  $\beta$ -naltrexamine **5** (342 mg, 1 mmol), and  $NaHCO_3$  (840 mg) in toluene–diglyme (15 mL, 2:1) was heated under  $N_2$  at 110 °C for 10 h. After filtration and removal of solvents in vacuo, the crude product was dissolved in 0.5 N HCl (10 mL) and extracted with EtOAc (25 mL × 3). The aqueous phase was rendered basic (pH 9) with  $NH_4OH$ , and the liberated free base was extracted with EtOAc (25 mL × 4). After removal of the solvent in vacuo, the crude product was chromatographed on silica gel with EtOAc–MeOH– $NH_4OH$  (85:15:0.5) to give 300 mg (50%) of **6**,  $R_f$  0.31 (EMA, 85:15:1), which was converted to the HCl salt (hygroscopic); mp 105–110 °C; CIMS,  $m/e$  603 ( $M^+$ ); NMR ( $Me_2SO-d_6$ )  $\delta$  6.85 and 6.76 (2 H, q, Ar), 7.85 (4 H, m, phthalimide, Ar), 4.92 (1 H, d, C-5 H), 3.81–3.50 (12 H, m,  $CH_2O$ ); IR (KBr)  $cm^{-1}$  1777 and 1715 (C=O, phthalimide). Anal. ( $C_{34}H_{41}N_3O_7 \cdot 2HCl \cdot 0.5H_2O$ ) C, H, N.

**1-Amino-8-( $\beta$ -naltrexamino)-3,6-dioxaoctane Trihydrochloride (2·3HCl).** A solution of 6·2HCl (340 mg, 0.563 mmol) and hydrazine (96 mg, 3 mmol) in EtOH (5 mL) was stirred at 23 °C for 2 days. The solvent was removed in vacuo and the residue was stirred at 23 °C with HCl (1 N, 10 mL) for 5 h. After removal of the insoluble phthalhydrazide by filtration and evaporation of the solvent in vacuo, the crude product was chromatographed on silica gel with EtOAc–MeOH– $NH_4OH$  (80:20:1) to give **2** an oil (229 mg, 0.48 mmol, 96%);  $R_f$  0.35 (EMA, 50:50:5). The free base was converted to the 3HCl salt with 1 N HCl in 2-propanol; mp 190–193 °C dec; EIMS,  $m/e$  472.9 ( $M^+$ ); NMR ( $Me_2SO-d_6$ )  $\delta$  9.58 (1 H, s, OH phenolic), 9.37 (1 H, br s,  $H^+N$ ), 8.96 (2 H, br,  $nal-N^+H_2$ ), 8.12 (3 H, br s,  $N^+H_3$ ), 6.80 and 6.67 (2 H, q,  $J = 8.2$  Hz, Ar), 6.43 (1 H, br s, C-14 OH), 5.00 (1 H, d,  $J = 7.1$  Hz, C-5 H), 3.78–3.58 (12 H, t and m,  $CH_2O$ ). Anal. ( $C_{26}H_{39}N_3O_5 \cdot 3HCl \cdot 3H_2O$ ) C, N, H: calcd, 7.1; found, 8.09.

**1-Guanidino-8-( $\beta$ -naltrexamino)-3,6-dioxaoctane Sulfate (3·1.5H<sub>2</sub>SO<sub>4</sub>).** A solution of **2** (46 mg, 0.097 mmol) and methyl isothiurea sulfate (28 mg, 0.1 mmol) in aqueous ethanol (50%, 3 mL) was stirred at 100 °C for 25 h. Sulfuric acid (1.8 N, 2 mL) then was added to the cold mixture. After removal of solvents in vacuo, the product was purified by gel filtration on Sephadex (LH-20) with MeOH to give the product, mp 155–160 °C (foaming);  $R_f$  0.19 (EMA, 50:50:10); NMR ( $Me_2SO-d_6$ )  $\delta$  9.45 (1 H, s, OH phenolic), 7.30 (5 H, br s,  $NHC(NH_2)_2^+NH_2$ ), 6.68 and 6.61 (2 H, q,  $J = 8$  Hz, Ar), 4.96 (1 H, d, C-5 H), 3.88–3.45 (12 H, m,  $CH_2O$ );  $^{13}C$  NMR 157.1 ( $NHC(NH_2)_2^+$ ), 69.80, 69.64, and 69.23 ppm ( $CH_2O$ ). Anal. ( $C_{27}H_{41}N_5O_5 \cdot 1.5H_2SO_4 \cdot 1.5H_2O$ ) C, H.

**1-(Benzylamino)-8-( $\beta$ -naltrexamino)-3,6-dioxaoctane Trihydrochloride (4·3HCl).** To a refluxing toluene (15 mL) solution of triethylene glycol ditosylate<sup>12</sup> (4.0 g, 8.76 mmol) containing  $NaHCO_3$  (1 g) was added over a 2-h period 1 g of  $\beta$ -naltrexamine **5** in 15 mL of toluene–diglyme (2:1). The reaction was conducted under  $N_2$  at 110 °C for an additional 5 h. After filtration and removal of solvents in vacuo, the excess of ditosylate was removed by dissolving the crude product in 1 N HCl (10 mL) and extracted with EtOAc (30 mL × 3). The aqueous phase containing the product was basified with  $NH_4OH$  (pH 9) and extracted with EtOAc (25 mL × 5). After removal of the solvent in vacuo, the crude intermediate compound **7**<sup>1</sup> was purified by gradient elution chromatography using silica gel and EtOAc–MeOH– $NH_4OH$  (99:1:0.5 to 80:20:1). The product (440 mg, 0.7 mmol) was isolated as a glass;  $R_f$  0.67 (EMA, 70:30:4); CIMS,  $m/e$  455 ( $M - TsOH$ ); NMR ( $CDCl_3$ )  $\delta$  7.83 and 7.40 (4 H, q, Ts, Ar), 6.71 and 6.54 (2 H, q,  $J = 8.2$  Hz, Ar), 4.51 (1 H d,  $J = 7.97$  Hz, C-5 H), 3.98–3.57 (12 H, m,  $CH_2O$ ). To a solution of **7** (160 mg, 0.28 mmol) in toluene–diglyme (5 mL, 2:1) containing  $NaHCO_3$  (120 mg) was added a solution of benzylamine (61 mg, 0.57 mmol) in toluene (1 mL). The reaction that was conducted under  $N_2$  was stirred at 110 °C for 6 h. After filtration and removal of solvent in vacuo, the crude product was chromatographed on silica gel with EtOAc–MeOH– $NH_4OH$  (85:15:1) to give the **4** as an oil (30 mg, 0.053 mmol), which was converted to the 3HCl salt (hygroscopic);  $R_f$  0.25 (EMA, 80:20:2); CIMS,  $m/e$  563 ( $M^+$ ); NMR ( $D_2O$  exchanged in  $Me_2SO-d_6$ )  $\delta$  7.47 (5 H, m, Ar), 6.82 (2 H, Ar), 4.98 (1 H, d, C-5 H), 3.92–3.52 (12 H, m,  $CH_2O$ ). Anal. ( $C_{33}H_{45}N_3O_5 \cdot 3HCl \cdot 3H_2O$ ) C, H, N: calcd, 5.80; found, 5.16.

**Acknowledgment.** This research was supported by NIDA Grant DA 02659. We thank Michael Powers and Barbara Taylor for the capable technical assistance in performing the biological testing.

## *Additions and Corrections*

1986, Volume 29

**Reinhard Sarges,\* Harry R. Howard, Kathy M. Donahue, Williard M. Welch, Beryl W. Dominy, Albert Weissman, B. Kenneth Koe, and Jon Bordner:** Neuroleptic Activity of Chiral *trans*-Hexahydro- $\gamma$ -carboline.

Page 19. The supplementary material paragraph was inadvertently omitted. It should read as follows: Listings of coordinates and bond angles and distances, anisotropic temperature factors, hydrogen coordinates, and observed and calculated structure factors and a stereoscopic view of molecule **8** are available as supplementary material (26 pages). Ordering information is given on any current masthead page.